Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. 1997

R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
Virology Research Group, Southern Research Institute-Frederick Research Center, Maryland 21701, USA.

A series of compounds related to oxathiin carboxanilide has been identified as nonnucleoside reverse transcriptase inhibitors (NNRTIs) of HIV-1, and structure-activity relationships have been described (Buckheit RW, et al.: Antimicrob Agents Chemother 1995;39:2718-2727). Three new analogs (UC040, UC82, and UC781) inhibited laboratory and clinical isolates of HIV-1, including isolates representative of the various clades of HIV-1 found worldwide, in both established and fresh human cells. Virus isolates with the amino acid changes L100I, K103N, V106I, and Y181C in the reverse transcriptase were partially resistant to these compounds. However, UC781 inhibited these virus isolates at low nontoxic concentrations, presenting a broad in vitro therapeutic index. As with other NNRTIs, each of the compounds synergistically interacted with AZT to inhibit HIV-1 replication. UC781 possesses a favorable pharmacokinetic profile in mice with a high level of oral bioavailability. Plasma concentrations reached maximum levels within 2 to 4 hr of oral administration and remained in excess of those required for in vitro anti-HIV activity for at least 24 hr after a single oral dose. When evaluated in a murine hollow fiber implant model of HIV infection, UC781 dosed orally or parenterally was able to suppress HIV replication completely in this model system, providing evidence of the in vivo efficacy of the compound.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008815 Mice, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation. Inbred Mouse Strains,Inbred Strain of Mice,Inbred Strain of Mouse,Inbred Strains of Mice,Mouse, Inbred Strain,Inbred Mouse Strain,Mouse Inbred Strain,Mouse Inbred Strains,Mouse Strain, Inbred,Mouse Strains, Inbred,Strain, Inbred Mouse,Strains, Inbred Mouse
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000813 Anilides Any aromatic amide obtained by acylation of aniline.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
June 1997, Biochemistry,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
April 1997, Journal of virology,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
October 2000, AIDS research and human retroviruses,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
May 2006, Journal of virology,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
February 2001, Antimicrobial agents and chemotherapy,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
October 2005, Antimicrobial agents and chemotherapy,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
June 2009, Antimicrobial agents and chemotherapy,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
November 2006, PLoS pathogens,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
October 2004, Current HIV research,
R W Buckheit, and M Hollingshead, and S Stinson, and V Fliakas-Boltz, and L A Pallansch, and J Roberson, and W Decker, and C Elder, and S Borgel, and C Bonomi, and R Shores, and T Siford, and L Malspeis, and J P Bader
January 2000, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!